Cardiologs Holter for Clinicians
Save time and treat more patients with unique arrhythmia diagnostic software
Software · Cloud SaaSCompany source
Company profile
About Cardiologs
Cardiologs is a medical AI company that develops innovative software solutions for cardiology diagnostics, utilizing clinically validated artificial intelligence to help reduce the burden of ECG analysis. The company aims to make cardiology diagnostics scalable and accessible to everyone by providing tools for clinicians and service providers across the globe to face the increased demand for cardiological diagnosis. The company's flagship product, the Cardiologs Holter Platform, is the first FDA-cleared ECG analysis solution powered by deep learning technology. With over 20 publications and abstracts, four patents, and more than 200 million ECGs processed, the platform helps diagnose over two million patients per year. The technology leverages medical-grade AI to alleviate the burden of redundant ECG analysis tasks, enabling clinicians to save time and treat more patients. Cardiologs is now part of Philips, operating under the Philips Professional Healthcare division. The company's solutions are designed specifically for arrhythmia diagnostics, providing advisory support to physicians and clinicians in conjunction with their clinical knowledge and patient information. The platform has demonstrated significant impact, with customers reporting the ability to triple their Holter activity while delivering faster diagnoses to more patients.
Company description Cardiologs official website
Mission. We aim to make cardiology diagnostics scalable and accessible to everyone.
Primary marketCardiology & Cardiovascular Health
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Cardiologs?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Arrhythmia
- Cardiac rhythm disorders
Who it serves
- Cardiac electrophysiologists
- Cardiology practices
- Clinicians
- Healthcare service providers
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsGlobal
Company sourceOfficial website
Company milestones
Platform expansion
Acquired by Philips and integrated into Philips Professional Healthcare division
Partnerships
Recorded partners
- Philips (acquired by/part of Philips Professional Healthcare)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Cardiologs Holter Platform
First FDA-cleared ECG analysis solution powered by deep learning technology
Software · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
A plug-and-play method for guided multi-contrast MRI reconstruction based on content/style modeling.Medical image analysis · Jun 20, 2026
DEEP-DISORDER: Motion Correction in 3D MRI via Segment Reconstruction and Registration.NMR in biomedicine · May 1, 2026
Convolutional recurrent U-net for cardiac cine MRI reconstruction via effective spatio-temporal feature exploitation.Medical physics · Jan 1, 2026
Deep Learning Can Unmask Conduction Tissue Disease From an Ambulatory ECG.Circulation. Arrhythmia and electrophysiology · Sep 1, 2025
Near-term prediction of sustained ventricular arrhythmias applying artificial intelligence to single-lead ambulatory electrocardiogram.European heart journal · Jun 2, 2025
State of the art of mobile health technologies use in clinical arrhythmia care.Communications medicine · Oct 29, 2024
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Holter activity volume
Customer reported ability to triple Holter activity in 2 years while delivering faster diagnoses
Patient diagnoses
Over two million patients diagnosed per year using the platform
ECG processing volume
Over 200 million ECGs processed
Institut Cardiovasculaire Paris-Sud (ICPS)
Scaling Holter monitoring capacity to handle increased diagnostic demand
Tripled Holter activity in 2 years, delivering faster diagnoses to more patients
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Dr. Laurent Fiorina
Cardiac Electrophysiologist
06 · Company updates
Updates from Cardiologs
Recent articles published on Cardiologs's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Cardiology & Cardiovascular Health
Companies applying AI to cardiovascular disease detection, ECG/EKG analysis, heart failure management, cardiac imaging, arrhythmia detection, or cardiovascular risk assessment. Includes AI-powered cardiac diagnostics, non-invasive hemodynamic monitoring, and tools for early detection and personalized management of heart conditions.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.